Latest Conference Articles

In this investigation, the second stage of the CHAMP phase 3 trial assessed the impact of prolonging drug administration for an extra 12 months on myopia control and the occurrence of myopia rebound upon cessation of dosing.

This study also investigated the development of myopia rebound when dosing was discontinued

Antonio Filipe Macedo, OD, MSc, PhD, speaks about his ARVO presentation on vision-related activity difficulties in patients with neovascular age-related macular degeneration

New research findings presented at this year's ARVO meeting compare two groups of paediatric patients in Nepal

Susana Chung, OD, PhD, spoke with us to discuss her presentation titled, "How similar is reading with central vision loss to reading in normal peripheral vision?" at this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9.

Susana Chung, OD, PhD, speaks about one of her ARVO presentations and the future of artificial intelligence in eye care

At this year's ARVO meeting, new data from the BLINK2 study show axial growth rates after discontinuing soft multifocal contact lens wear

David A Berntsen, OD, PhD, FAAO, sat down to discuss his presentation at this year's ARVO meeting held in Seattle, Washington, about axial growth after discontinuing soft multifocal contact lens wear in the BLINK2 study.

Age of vision loss onset has a stark impact on patients’ auditory processing and sensory substitution

Philip P. Storey, MD, shares the highlights of his ARVO presentation on a post hoc analysis of the pivotal TENAYA/LUCERNE trials.

At this year's ARVO meeting, Ash Abbey, MD, Director of clinical research at Texas Retina Associates, presented 36-month data from the GALE study of pegcetacoplan for the treatment of dry age-related macular degeneration specifically geographic atrophy.

With the progression of MS, thinning of the retinal ganglion cell (RGC) complex is seen as well as a decrease in the amplitude of the pattern electroretinogram (pERG)

Study data demonstrated a significant correlation between visual function, structure and neurological impairment in an experimental autoimmune encephalomyelitis model

Deborah Ristvedt, DO, in her Controversies in Modern Eye Care presentation, discussed the evolution from traditional glaucoma treatments to novel therapies that target the trabecular meshwork and that aim to optimize IOP management without the need for multiple medications.

Inder Paul Singh, MD, highlights how early intervention, modern techniques, and reduced medication burden can improve outcomes and quality of life for patients with glaucoma in his presentation at the Controversies in Modern Eye Care conference.

Kelsey Roelofs, MD, shares some useful tips for identifying and diagnosing thyroid eye disease for attendees of the 18th Annual Controversies in Modern Eye Care symposium.

James A. Katz, MD, discussed evolving treatments for Demodex blepharitis, highlighting traditional methods like tea tree oil and microblepharoexfoliation as well as a newer FDA-approved therapy, and emphasizing the need to examine the upper eyelid carefully to diagnose the condition.

The 18th annual Controversies in Modern Eye Care conference, held on May 4, 2024, in Los Angeles, was co-chaired by Neda Shamie, MD, and Arjan Hura, MD, with the aim of discussing the latest advancements in eye care.

Hura highlighted some of the key takeaways from the Controversies in Modern Eye Care symposium where presenters and attendees shared their insights into the latest advancements in refractive surgery, retina care, and collaborative eye care.

Dr Richard Lindstrom speaks about the future of dry eye and shares pearls for young eye surgeons

Ahead of the meeting, several companies previewed product pipeline announcements and research data presentations

The meeting kicks off with symposia and an opening keynote speech from Ed Yong

Rick Lewis, chief medical officer of ViaLase, describes the company's nonincisional glaucoma treatment, showing promising safety and efficacy in studies and possibly paving the way for FDA approval.

More companies have released information on presentations related to their pipelines and new data at the ARVO 2024 conference.

As the annual ARVO conference draws closer, more companies have released information on presentations related to their pipeline and new data.

Neda Nikpoor, MD, urges audience members to become more empowered in making small but meaningful, evidence-based changes in combating unconscious gender bias.

George O. Waring IV, MD, FACS, highlighted preliminary data from an open-label clinical trial, where his site was 1 of 4 in the US.

Deborah Gess Ristvedt, DO, shares highlights from her presentation and what these real-world cases mean for clinicians and their patients with glaucoma.